絞り込み

16641

広告

めおと漫才 宮川花子さん 多発性骨髄腫を公表 (NHK)

めおと漫才の人気コンビ「宮川大助・花子」の宮川花子さんが11日、血液のがんの一種、多発性骨髄腫であることを公表しました。 宮川花子さんは、ことし6月から体調不良...

  1. ノーベル化学賞受賞の吉野さん 母校にメッ...
  2. 乳幼児編が加わった「抗微生物薬適正使用の...
  3. 【オススメ】バンクーバー、ダウンタウン観...
  4. 【書評】そう、人の意見は変えられないのだ...

ニュース一覧

「elotuzumab」の検索結果

248件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

A Novel Approach to Remove Interference of Therapeutic Monoclonal Antibody with Serum Protein Electrophoresis.

[Management of multiple myeloma in the relapsed/refractory patient].

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of NF-κB pathways.

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Treatment of relapsed multiple myeloma: Evidence-based recommendations.

Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma.

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study.

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.

Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.

Increased SLAMF7 monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります